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Abstract
Importance—Increases in testosterone use and mixed reports of adverse events have raised 
concerns about the cardiovascular safety of testosterone. Testosterone is available in several 
delivery mechanisms with varying pharmacokinetics; injections cause spikes in testosterone 
levels, while transdermal patches and gels cause more subtle but sustained increases. The 
comparative cardiovascular safety of gels, injections and patches has not been studied.
Objective—To determine the comparative cardiovascular safety of testosterone injections, 
patches, and gels.
Design—Retrospective cohort study.
Setting—Administrative claims from a commercially-insured and Medicare population in the 
United States, and general practitioner records from the United Kingdom, years 2000 – 2012
Participants—Adult (18+), male initiators of testosterone patches, gels, or injections following 
180 days free of any testosterone use
Exposure—New initiation of a testosterone dosage form, followed for up to one year
Main Outcomes and Measures—In- or outpatient medical records, diagnoses, or claims for: 
cardio- and cerebrovascular events, including myocardial infarction (MI), unstable angina, stroke, 
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composite acute event (MI, unstable angina, or stroke); venous thromboembolism (VTE); 
mortality, and all-cause hospitalization.
Results—We identified 431,687 testosterone initiators between the 3 datasets: 36% injection, 9% 
patch, 55% gel. Medicare had a majority of injection initiators (51%); the US commercially-
insured population had majority gel initiators (56%); the United Kingdom had equal proportions 
of injections and gels (~41%). When compared to gels, injection initiators had higher hazards of 
CV events (MI, UA, and stroke) (HR=1.26, 95% CI: 1.18–1.35), hospitalization (HR=1.16, 95% 
CI: 1.13–1.18), and death (HR=1.34, 95% CI: 1.15–1.56), but not VTE (HR=0.92, 95% CI: 0.76–
1.11). Patches did not confer increased hazards of CV events compared to gels (HR=1.10, 95% CI: 
0.94–1.29), hospitalization (HR=1.04, 95% CI: 1.00–1.08), death (HR=1.02, 95% CI: 0.77–1.33), 
or VTE (HR=1.08, 95% CI: 0.79–1.47).
Conclusions and Relevance—Testosterone injections were associated with a greater risk of 
CV events, hospitalizations, and deaths compared with gels. Patches and gels had similar risk 
profiles. However, this study did not assess whether patients met criteria for use of testosterone 
and did not assess the safety of testosterone among users compared to non-users of the drug.
Background
Testosterone use has increased considerably in the United States (US), United Kingdom 
(UK) and other countries,1–5 and many initiators lack clear, documented indications for 
treatment1,4. Ongoing, unresolved concerns about cardiovascular safety have been raised by 
the halting of a randomized trial of testosterone gels in older men with limited mobility due 
to increased cardiovascular events6, and non-experimental studies reporting increased 
cardiovascular risk in older men with cardiovascular disease.7,8 Although the recent 
literature is mixed with some studies suggesting no harmful effects9–11, there has been 
considerable use contrary to recommended guidelines1,4, prompting interest and 
investigation into testosterone use and safety.
Testosterone is available in multiple dosage forms, including intramuscular injections, 
transdermal patches and gels, implantable pellets, intranasal sprays, and oral/buccal 
applications. While gels, injections, and patches all effectively raise testosterone levels, their 
pharmacokinetics differ; injections create spikes of super-normal testosterone levels which 
slowly decrease until a subsequent injection12; this cycling results in less time within normal 
ranges than with transdermal systems12. Gels and patches result in subtle, short-term 
increases in testosterone levels (24–48 hours), and daily reapplication can maintain 
consistent levels12. However, gels provide longer-lasting increases than patches13. As 
testosterone levels may influence short-term clotting and polycythemia, differing 
pharmacokinetics may result in varying safety profiles. We compared the cardiovascular risk 
of testosterone gels, injections, and patches in cohorts of real-world users drawn from large 
healthcare databases.
Methods
We conducted a new-user14 cohort study of testosterone injection, gel, and patch initiators in 
three secondary data sources: two from the US and one from the UK.
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The first US cohort consisted of commercially-insured men from the Truven MarketScan 
Commercial Claims and Encounters and Medicare Supplementary and Coordination of 
Benefit files (Truven Health Analytics, Inc., Ann Arbor, MI), 2000–2012. This database 
contains adjudicated insurance claims for in- and outpatient procedures and diagnoses and 
pharmacy-dispensed medications for those with employer-sponsored commercial insurance, 
spouses, dependents, and retirees with employer-sponsored Medicare supplementary plans 
from large, US employers. Supplementary laboratory test results were available for a subset 
whose labs were processed by a national laboratory testing company during the years 2007 – 
2012. We included men aged 18+ years.
The Medicare cohort was drawn from a national, random 20% sample of the US Medicare 
fee-for-service population, 2007 – 2010. It contains billing claims for procedures, diagnoses, 
and dispensed medications for adults aged 65+ from throughout the US. No laboratory test 
results were available in this cohort.
The UK cohort was drawn from the Clinical Practice Research Datalink (CPRD), a 
compilation of general practitioner (GP) medical records from throughout the UK from 
January 2000 to June 2012, which contains outpatient clinical characteristics, diagnoses and 
procedures, reported hospital and specialist notes, and prescribed medications as recorded by 
GPs. Laboratory results were available for most tests performed. We included men aged 18+ 
years.
Exposure assessment
We identified men newly initiating testosterone following a 180-day washout period free of 
documented testosterone use. Only the first eligible new-use period per individual was 
included. Considered testosterone dosage forms included: pharmacy-dispensed transdermal 
gels and patches; pharmacy-dispensed injections; or in-office injections from procedure and 
supply codes. Exposure categories were grouped as gel, injection, and patch. Prior use of 
implanted pellets, oral/buccal testosterone, and oral methyltestosterone during washout were 
considered exclusion criteria, but due to rare, esoteric use and documented risks of 
methyltestosterone-induced liver problems, these forms were not considered as exposures 
for the comparative analysis. Patients with claims for two different forms on the index day 
were excluded because their exposure could not be accurately categorized.
The date of the first pharmacy prescription or injection procedure code following the 
washout period was considered the index date for the new-user cohorts.14 Due to potential 
for differential adherence and discontinuation between the dosage forms (injections are 
dosed every several weeks and patches/gels are dosed daily), we employed a first-exposure-
carried-forward analysis where the patient was considered exposed continuously throughout 
follow-up (see eFigure 1).
Outcome assessment
We followed initiators for up to one year to observe outcomes, including: myocardial 
infarction (MI); unstable angina; stroke; composite acute events (MI, unstable angina, or 
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stroke); all-cause hospitalization; mortality; and venous thromboembolism (VTE). The 
effects were estimated separately for each outcome, and those experiencing the outcome of 
interest during baseline were excluded to restrict to new-onset outcomes. Only the first 
occurrence of each outcome during follow-up was considered.
In MarketScan and Medicare, outcomes were based on International Classification of 
Diseases 9th Revision, Clinical Modification (ICD-9) diagnosis codes. MI, unstable angina, 
and stroke required an inpatient diagnosis of the condition with a hospital stay of at least one 
day.15,16 All-cause hospitalization was defined as hospitalization for any reason. VTE was 
defined an as inpatient diagnosis claim followed by a prescription for an antithrombotic drug 
in the following 30 days.17,18 Mortality was unavailable in MarketScan.
In the CPRD, outcomes were assessed using Read codes recorded by the GP or reported to 
the GP from hospitals or specialists.19,20
Covariates
We identified total serum testosterone tests performed during the baseline period with 
procedure codes. If a test result was available, the test result was categorized as ‘high,’ 
‘normal,’ or ‘low’ according to assay-specific result flags or reference ranges. If flags or 
ranges were unavailable, we classified the result as: ‘low’, <300 mg/dL (10.4 nmol/L); 
‘normal’, 300–849 ng/dL (10.4–25.4 nmol/L); ‘high’, ≥850 ng/dL (29.5 nmol/L).
Other covariates were assessed during the baseline period using diagnosis, procedure, and 
medication codes and included: calendar year; age; comorbidity; cardiovascular risk factors; 
healthcare utilization; preventive and screening care; indications for testosterone; and other 
medication use. Due to the medical records-based structure of the CPRD, body mass index 
(BMI) and smoking status were available in the CPRD cohort.
Statistical analysis
Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using multivariable 
Cox proportional hazards models using days since initiation as the time scale; models were 
adjusted for a priori identified confounders. Censoring occurred at the first occurrence of: 
end of the study (MarketScan: December 31, 2012; Medicare: December 31, 2010; CPRD: 
June 30, 2012); one year post-index date; disenrollment; or death (except when death was 
the outcome of interest). Separate models for injections and patches were run using gels as 
the referent group as gels were the most commonly- and broadly-used form.
Additionally, we estimated the effects of testosterone dosage forms using propensity score 
(PS) matching. We estimated the predicted probability, or PS, of receiving the form of 
interest versus gels by modeling treatment received with the measured covariates as 
predictors in logistic regression models. Gel initiators were up-to-2:1 matched to initiators of 
injections or patches using a greedy matching algorithm which 1:1 matches without 
replacement to the 5th digit of the PS, if possible21; the algorithm then attempted to 1:1 
match the remaining, unmatched gel initiators to the treatment group, resulting in 1 or 2 
matched gel initiators for each injection or patch initiator. The HRs were then estimated in 
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the matched datasets, estimating the treatment effect among those treated with the dosage 
form of interest.22
Due to differences in database structure and covariate availability, analyses were performed 
and results presented separately in the three databases. Summary estimates were obtained by 
meta-analyzing the three database-specific multivariable adjusted estimates with fixed 
effects models.23
Sensitivity analyses
We repeated the analyses separately in subgroups of those with documented low or normal 
baseline testosterone levels and those without recent measurements to account for potential 
for differential prescribing by testosterone level. Additionally, to remove contraindicated use 
in prostate cancer patients, we performed the analysis excluding patients with diagnoses of 
prostate or any cancer. As usage patterns changed over time1, we performed an analysis 
restricted to later years after gels had become the predominant therapy option: 2007–2012. 
Due to a study suggesting cardiovascular risk increased relatively soon after testosterone 
initiation,7 we performed an analysis following patients for only 6 months. We also 
performed an as-treated analysis in MarketScan where initiators’ follow-up time was 
censored at treatment discontinuation or switching from the index testosterone dosage form, 
or at one-year for continuous users. As there are multiple injectable testosterone 
formulations, we also separately considered injection testosterone cypionate, enanthate, and 
propionate formulations compared to gels.
Study logistics
We performed analyses using SAS 9.2 (SAS Institute, Cary, NC) and Episheet Spreadsheets 
for the Analysis of Epidemiologic Data. This project was approved by the Institutional 
Review Board of the University of North Carolina at Chapel Hill (IRB number 12–1490). 
The protocol was also approved by the Independent Scientific Advisory Committee of the 
CPRD, Medicines & Healthcare Products Regulatory Agency on May 17, 2013. Written 
consent was not required from study participants.
Results
We identified 487,131 eligible testosterone initiators in MarketScan (60% gel, 39% 
injection, 1% patch), 22,376 in Medicare (43% gel, 51% injection, 6% patch), and 6,607 in 
the CPRD (42% gel, 40% injection, 18% patch).
In MarketScan, gel, injection, and patch initiators tended to be similar, with a few notable 
exceptions. Mean age was similar between the three forms, but patch initiation was 
concentrated much earlier in the study period than other dosage forms, and gels were 
concentrated later. As testing became more common over the time period, gels had more 
total testosterone lab testing prior to gel initiation, but injections had more recorded ICD-9 
or Read code diagnoses of hypogonadism. Additionally, gel initiators received more 
prostate-specific antigen (PSA) tests and lipid profiles (see Table 1 for selected covariates; 
full covariate distributions are shown in eTable 1). Of the testosterone injection initiators, 
83% were testosterone cypionate, 9% testosterone enanthate, and 1% testosterone 
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propionate; 55% of injections were in-office injections, 44% were pharmacy-dispensed (1% 
had both on the same day). In the 6 months post-initiation, 36% of gel users had a serum 
total testosterone test, 32% of injection users, and 28% of patch users.
The Medicare cohort was older on average than the MarketScan or CPRD cohorts. 
Characteristics were similar between the dosage forms, as the Medicare cohort was drawn 
from a narrower time period. However, patch initiators reported more heart failure and 
psychiatric disorders. Gel initiators had more recorded hypogonadism diagnoses and PSA 
screening, while patch initiators had fewer sexual dysfunction diagnoses. In the 6 months 
after initiation, more gel users (49%) had follow-up testosterone measurements than 
injections (39%) or patches (40%). Some characteristics were not displayed due to small 
cohort size restrictions in our data use agreement with the Centers for Medicare & Medicaid 
Services. See eTable 2 for complete covariate distributions.
Among the CPRD cohort, a much larger proportion of injection initiators did not have a 
recent testosterone measurement. Gel initiators tended to occur later in the time period, and 
gel initiators had more diagnoses of hypogonadism and PSA screening. There was also less 
statin use among the injection initiators (see eTable 3).
One-year incidence of cardiovascular events was low among the younger MarketScan and 
CPRD testosterone initiators, but more common in the older Medicare initiators (see Tables 
2 and 3). Hospitalization rates were higher in the US databases than in the CPRD, and 
mortality was more frequent in Medicare. VTE rates were very low due to the restrictive 
definition meant to ensure true cases. In all databases, gel initiators tended to have lower 
crude rates of all outcomes than injection or patch initiators (see eFigure 2).
For the injection versus gel comparisons, we observed elevated crude HRs for most 
outcomes in all datasets. Upon adjustment, most effect measure estimates were attenuated, 
yet all remained elevated (see Table 2 and Figure 1), except for VTE. PS-matched estimates 
generally closely agreed with the adjusted estimates.
For the patch versus gel comparisons, the crude VTE HR estimates were null in all 
databases, and the crude CPRD death effect estimate was slightly protective; all other 
unadjusted estimates were above the null. Due to small sample sizes and limited number of 
events, some adjusted effect measures could not be estimated. Upon adjustment and PS-
matching, the crude HR estimates attenuated toward the null, suggesting no or slight 
increases in risk in patch initiators compared to gel, although smaller sample sizes resulted 
in less precise effect measure estimates (see Table 3 and Figure 2). PS matched estimates 
and adjusted estimates were very similar.
Results from the three databases generally agreed, although the MarketScan estimates 
tended to be closest to the null, followed by Medicare, with the CPRD estimates the most 
extreme (see Figures 1 and 2).
In analyses within testosterone level subgroups, small samples resulted in imprecise, 
unstable estimates (see eTables 4 and 5). Although they agreed with overall analyses in 
direction of effect, they should be interpreted cautiously. When excluding patients with prior 
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cancers, results were similar to the overall estimates (see eTables 6 and 7). When 
considering initiation during the years 2007–2012, no differences were observed from the 
overall sample (see eTable 8), and when considering a 6-month follow-up period, results 
were also similar (see eTable 9). The as-treated analysis in MarketScan generally yielded 
HRs slightly higher than the estimates from the first-exposure-carried-forward analysis, but 
the conclusions generally agree with the primary analysis (see eTable 10). Mean treatment 
duration in days, (SD) was: gel, 122 (112); injection, 105 (104); and patch, 96 (91). When 
considering injection formulations separately, testosterone cypionate and enanthate showed 
effect estimates very similar to the overall results (see eTable 11); testosterone propionate 
was used rarely, and estimates were imprecise, but were consistent with the overall 
estimates.
Discussion
In this multi-cohort comparison of testosterone dosage forms, we observed consistent 
increases in the risk of cardio- and cerebrovascular events, hospitalization, and death among 
injection initiators compared with gels. When comparing patches with gels, we observed a 
slight increase in myocardial infarction among patch initiators, but all other outcomes were 
inconsistent. We did not observe any dosage form carrying a higher risk of VTE than others. 
While the increased risk of outcomes in injection initiators was consistent across databases, 
absolute incidences were small in this relatively short time period. In Medicare—the cohort 
with the oldest average population—one-year incidence of the composite MI, angina, and 
stroke outcome was 23.1 events / 1,000 person-years in gels, 36.6 in injections, and 34.9 in 
patches. In MarketScan and CPRD, outcome occurrence was lower, and even consistently 
increased relative risks translated into low absolute increases.
While prior safety research has investigated testosterone as a class,6–8,24,25 this study 
directly compared individual dosage forms. A prior CPRD study demonstrated that 
hypertension and polycythemia risk was higher in injection versus oral testosterone,26 
suggesting that dose forms’ risk profiles do differ. A reanalysis of the Testosterone in Older 
Men with Mobility Limitations trial found that gel users who experienced adverse 
cardiovascular events had greater increases in serum free testosterone.27 Different dosage 
forms lead to different serum testosterone levels over time—injections result in spikes and 
periods of super-normal levels12—possibly accounting for observed CVD risk.
This analysis is subject to limitations inherent in the use of secondary healthcare data: 
unavailability of important patient characteristics; missing data; the non-randomized nature 
of the exposure; and potential outcome misclassification. Some predictors of cardiovascular 
events, such as smoking status and BMI, were unavailable in the US cohorts. However, they 
were available in the CPRD, and using a variety of cohorts allowed us to estimate the effect 
in settings with and without these potential confounders. The CPRD estimates generally 
agreed with the US-based estimates, and obesity was evenly-distributed between treatments 
(see eTable 3) and did not contribute substantially to the injection vs. gel outcome model for 
the composite event (β=-0.13, p=0.80). Smoking status was slightly imbalanced between 
treatments, and being a current smoker did contribute to the outcome model (β=0.78, 
p<0.0001). However, we compared models in the CPRD adjusted for obesity and smoking 
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(HR=0.75, 95% CI: 0.42–1.33) to those not adjusted for them (HR=0.70, 95% CI: 0.39–
1.24), and they did not vary substantially.
Additionally, hypogonadism symptoms can be diffuse and indistinct, and they were 
infrequently diagnosed and coded, often leaving us without the primary indications for 
testosterone treatment. However, by comparing new initiators of various forms, we 
restricted to those determined to require treatment by a clinician, and choice of form is likely 
not heavily influenced by indication or cardiovascular risk. However, important unmeasured 
behavioral, economic, or social differences between treatment groups may remain. All the 
included men have insurance coverage, but injections tend to be less expensive than branded 
gels and can be administered by healthcare providers; therefore, in-office injections may be 
prescribed more frequently to those with reduced personal disease-management skills or 
resources and subsequent higher cardiovascular risk. Gel initiators received more post-
initiation follow-up serum testosterone tests, possibly indicating better health management 
and physician monitoring. However, patches had lower post-initiation monitoring similar to 
injections, yet similar increased event rates were not observed. In most measured clinical 
respects, initiators of various dosage forms were not meaningfully different.
Additionally, time trends in testosterone testing and treatment exist, with both becoming 
more common later in the study period.1 The proportion of initiators using a gel as their 
index prescription has increased, with injection and patch use decreasing over the study 
period.1 Increased cardiovascular risk in injections versus gels may be a function of 
comparing an older, sicker patient case mix early in the study period to healthier gel 
initiators. However, we do not see the same patterns when comparing patches to gels, and 
patches were prescribed even earlier, on average, suggesting that the observed effects are not 
merely time trends. We adjusted for calendar year, and sensitivity analyses considering only 
the later years of the study did not show different effects.
Many patients initiated testosterone without recorded serum testosterone tests or relevant 
diagnoses, and we did not require evidence of usage according to guidelines28 for inclusion 
in the cohort. Due to inadequate information on pre- and post-initiation testosterone levels, 
we could not measure the impact of achieved blood levels. We did not adjust for baseline 
testosterone levels in the primary analyses. Baseline testosterone levels were unavailable in 
Medicare and for the majority of MarketScan initiators. Additionally, many individuals did 
not have a serum testosterone level measured in the 6 months prior to initiation (MarketScan 
37%, Medicare 34%, CPRD 54%); some baseline tests may be missing due to out-of-pocket 
payment, use of other insurance coverage, or failure to bill/record, although treatment in 
men without levels or with normal levels has been observed1. However, treatment choice 
could not be influenced by baseline testosterone levels in those without measurements, and 
levels were not strongly associated with choice of dosage form in those with baseline 
measurements. Selection bias may be introduced by restricting only to those with tests 
performed and results available, therefore, we adjusted for having a baseline test performed, 
but not for the result.
Different routes of testosterone administration may lead to differential non-adherence. Gel 
and patch use were assessed through pharmacy dispensing (US) or written prescriptions 
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(UK), while injections were assessed from both pharmacy information and in-office 
procedure codes. We could not measure whether the written prescriptions (UK) were 
actually dispensed or the dispensed prescriptions (US) were used, whereas codes for in-
office injections have much lower potential for non-receipt than pharmacy prescriptions 
leading to potential differences in misclassification due to non-adherence between dosage 
forms. However, 45% of injection users in MarketScan initiated with pharmacy-dispensed 
injections, allowing for greater non-adherence than in-office injections.
Additionally, claims-based studies have the potential for outcome misclassification as claims 
are generated for billing rather than research. In the US cohorts, we utilized restrictive 
claims-based definitions for MI, angina, stroke, and VTE to avoid inclusion of rule-out 
diagnoses. Similar definitions in other studies have demonstrated very high specificity,15,18 
and thus we estimated relative measures of effect rather than absolute which will be 
unbiased in the presence of nondifferential outcome misclassification.29 However, 
differences in diagnosing, reporting, and recording between the databases may have resulted 
in the different magnitudes of effect estimates observed between databases.
While the study was limited by the non-randomized nature of the exposure, this study 
benefits greatly from the large, diverse patient sample representing patients across age 
groups, populations, treatment and practice patterns, and healthcare systems. MarketScan is 
representative of those with employer-sponsored commercial insurance in the US, and our 
Medicare cohort came from a random 20% sample of Medicare beneficiaries from 
throughout the US. The CPRD is widely representative of primary medical practice in the 
UK where testosterone use is more restrained,1 pharmaceutical advertising is limited, and 
there is less disparity in healthcare access. Despite of these differences, effect measure 
estimates generally agreed across cohorts, suggesting robustness of the results.
Our analysis suggests that testosterone injections may increase the short-term risk of 
cardiovascular events, stroke, death, and hospitalization compared with gels. The risks from 
patches and gels appeared similar, and lower than injections. With potential long-term 
effects of testosterone on lipids, further exploration of longer-term testosterone treatment on 
cardiovascular risk is warranted. With continuing concern about the safety and effectiveness 
of testosterone treatment in men with primary and age-related hypogonadism and the trend 
of treatment of men with normal testosterone levels or without recent baseline testing, it is 
important to understand the potential hazards of testosterone treatment.
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Forrest plot of adjusted hazard ratios (aHR) for the risk of outcomes in injection versus gel 
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Forrest plot of adjusted hazard ratios (aHR) for the risk of outcomes in patch versus gel 
testosterone initiators
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